KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Medpace Holdings (MEDP) EBIT (2016 - 2025)

Historic EBIT for Medpace Holdings (MEDP) over the last 11 years, with Q4 2025 value amounting to $153.3 million.

  • Medpace Holdings' EBIT rose 2224.55% to $153.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was $534.9 million, marking a year-over-year increase of 1970.71%. This contributed to the annual value of $534.9 million for FY2025, which is 1970.71% up from last year.
  • As of Q4 2025, Medpace Holdings' EBIT stood at $153.3 million, which was up 2224.55% from $141.8 million recorded in Q3 2025.
  • In the past 5 years, Medpace Holdings' EBIT ranged from a high of $153.3 million in Q4 2025 and a low of $42.4 million during Q2 2021
  • Over the past 5 years, Medpace Holdings' median EBIT value was $85.6 million (recorded in 2023), while the average stood at $89.8 million.
  • As far as peak fluctuations go, Medpace Holdings' EBIT fell by 24.19% in 2021, and later soared by 4489.42% in 2022.
  • Quarter analysis of 5 years shows Medpace Holdings' EBIT stood at $54.9 million in 2021, then skyrocketed by 39.33% to $76.4 million in 2022, then rose by 14.25% to $87.3 million in 2023, then skyrocketed by 43.58% to $125.4 million in 2024, then rose by 22.25% to $153.3 million in 2025.
  • Its EBIT stands at $153.3 million for Q4 2025, versus $141.8 million for Q3 2025 and $126.3 million for Q2 2025.